In this video, health-care analyst David Williamson discusses how Big Pharma is attempting to catch up when it comes to creating a next-gen hepatitis-C cure. Today's news features a collaboration between Merck and Bristol-Myers Squibb. Has Big Pharma missed the boat, or is there still time to get on board with a winning combination? Watch and find out.
Big Pharma Frantically Plays Catch-Up
By Dave Williamson
-
Apr 22, 2013 at 8:00PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can it still make up ground with a winning hep-c drug cocktail?
Stocks Mentioned

Merck & Co., Inc.
MRK
$93.55
(1.58%)
$1.46

Johnson & Johnson
JNJ
$176.98
(1.75%)
$3.04

Gilead Sciences, Inc.
GILD
$63.84
(0.90%)
$0.57

Bristol Myers Squibb Company
BMY
$76.19
(0.30%)
$0.23

AbbVie Inc.
ABBV
$151.01
(-0.47%)
$0.71
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Better Buy: Gingko Bioworks vs. Amyris

Have $2,000? 2 Market Crash-Ready Stocks to Buy

Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever

2 Safe Stocks to Buy in a Bear Market

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.